Fostemsavir salvage therapy continues to look good at 96 weeks
Dolutegravir dual therapy works well for both first line and maintenance treatment
First trial results of new immune-modulating drugs presented in Mexico City
Islatravir plus doravirine may offer new dual therapy option
Four days on, three days off HIV treatment as effective as continuous therapy, French study finds
ADVANCE trial shows dolutegravir is highly effective in South Africa
PrEP implant could last well over a year
Dolutegravir leads to weight gain in two African studies
People with HIV express high satisfaction with monthly injectable regimen
